Agile Therapeutics Cash Flow from Investing Activities 2013-2023 | AGRX
Agile Therapeutics cash flow from investing activities from 2013 to 2023. Cash flow from investing activities can be defined as the total change in cash resulting from a companies investments
Agile Therapeutics Annual Cash Flow Investing
(Millions of US $) |
| 2023 |
$ |
| 2022 |
$-0 |
| 2021 |
$39 |
| 2020 |
$-41 |
| 2019 |
$-0 |
| 2018 |
$-0 |
| 2017 |
$-1 |
| 2016 |
$-0 |
| 2015 |
$-0 |
| 2014 |
$-0 |
| 2013 |
$-5 |
| 2012 |
$-7 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.003B |
$0.020B |
|
Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. It is focused on the development and commercialization of new prescription contraceptive products. The Company's lead product candidate is Twirla (TM), also known as AG200-15, a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Agile Therapeutics, Inc. is headquartered in Princeton, New Jersey.
|
